Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Long-Term Deferred Tax (2020 - 2023)

Maravai Lifesciences Holdings has reported Long-Term Deferred Tax over the past 4 years, most recently at $773.7 million for Q3 2023.

  • Quarterly results put Long-Term Deferred Tax at $773.7 million for Q3 2023, changed 0.33% from a year ago — trailing twelve months through Sep 2023 was $773.7 million (changed 0.33% YoY), and the annual figure for FY2022 was $765.8 million, down 5.24%.
  • Long-Term Deferred Tax for Q3 2023 was $773.7 million at Maravai Lifesciences Holdings, up from $769.6 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for MRVI hit a ceiling of $820.8 million in Q3 2021 and a floor of $419.9 million in Q1 2021.
  • Median Long-Term Deferred Tax over the past 4 years was $770.4 million (2022), compared with a mean of $705.9 million.
  • Peak annual rise in Long-Term Deferred Tax hit 88.9% in 2022, while the deepest fall reached 6.05% in 2022.
  • Maravai Lifesciences Holdings' Long-Term Deferred Tax stood at $431.7 million in 2020, then surged by 87.19% to $808.1 million in 2021, then fell by 5.24% to $765.8 million in 2022, then increased by 1.03% to $773.7 million in 2023.
  • The last three reported values for Long-Term Deferred Tax were $773.7 million (Q3 2023), $769.6 million (Q2 2023), and $767.0 million (Q1 2023) per Business Quant data.